Get the Stockscreener App
5.67
1.25%
0.07
Replimune Group Inc stock is traded at $5.67, with a volume of 2.27M.
It is up +1.25% in the last 24 hours and up +102.14% over the past month.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
See More
Previous Close:
$5.60
Open:
$5.6
24h Volume:
2.27M
Relative Volume:
0.28
Market Cap:
$442.58M
Revenue:
-
Net Income/Loss:
$-209.96M
P/E Ratio:
-1.7943
EPS:
-3.16
Net Cash Flow:
$-176.27M
1W Performance:
+1.98%
1M Performance:
+102.14%
6M Performance:
-59.44%
1Y Performance:
-44.08%
1-Day Range:
$5.53
$5.818
1-Week Range:
$5.08
$5.818
52-Week Range:
$2.68
$17.00
Replimune Group Inc Stock (REPL) Company Profile
Name
Replimune Group Inc
Sector
Industry
Phone
(781) 222-9600
Address
500 UNICORN PARK, WOBURN, MA
Compare REPL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REPL
Replimune Group Inc
|
5.67 | 416.04M | 0 | -209.96M | -176.27M | -3.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Replimune Group Inc Stock (REPL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Jul-23-25 | Downgrade | BMO Capital Markets | Outperform → Underperform |
| Jul-23-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jul-23-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-22-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-22-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jul-22-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-22-25 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-20-25 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-28-24 | Initiated | ROTH MKM | Buy |
| Apr-17-23 | Resumed | Piper Sandler | Overweight |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Nov-17-20 | Initiated | BTIG Research | Buy |
| Nov-02-20 | Initiated | Jefferies | Buy |
| Oct-15-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jul-01-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| May-05-20 | Initiated | Barclays | Overweight |
| Sep-04-19 | Initiated | ROTH Capital | Buy |
| Jul-23-19 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-08-19 | Initiated | H.C. Wainwright | Buy |
| Apr-25-19 | Initiated | Wedbush | Outperform |
| Jan-23-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-14-18 | Initiated | JP Morgan | Overweight |
| Aug-14-18 | Initiated | Leerink Partners | Outperform |
View All
Replimune Group Inc Stock (REPL) Latest News
REPL Investors Have the Opportunity to Lead the Replimune Securities Fraud Lawsuit with Faruqi & Faruqi, LLP - GlobeNewswire
Biotech Replimune Faces Derivative Suit Over Trial Claims - Law360
Replimune (REPL) Faces Securities Class Action Following - GlobeNewswire
Did You Lose Money on Replimune Group, Inc. (REPL)? Levi & Korsinsky Urges Investors to Act Before September 22, 2025 - ACCESS Newswire
Will Replimune Group Inc. see short term momentum2025 Buyback Activity & Stepwise Entry and Exit Trade Signals - Newser
US Bancorp DE Buys 3,921 Shares of Replimune Group, Inc. $REPL - Defense World
Using R and stats models for Replimune Group Inc. forecasting2025 Market Overview & Risk Managed Investment Entry Signals - Newser
What technical models suggest about Replimune Group Inc.’s comebackEarnings Overview Report & AI Forecasted Entry and Exit Points - Newser
Is Replimune Group Inc. stock reversal real or fakePortfolio Profit Report & Verified Momentum Stock Alerts - Newser
Applying big data sentiment scoring on Replimune Group Inc.July 2025 Spike Watch & Weekly Setup with High ROI Potential - Newser
Published on: 2025-08-19 23:50:57 - Newser
Replimune (REPL) Faces Securities Class Action Following Stock’s Collapse Amid FDA’s Rejection of Melanoma DrugHagens Berman - ACCESS Newswire
What moving averages say about Replimune Group Inc.Market Volume Report & Expert Curated Trade Setup Alerts - Newser
Investor Alert: Deadline Approaching to Join Replimune Group, Inc. (REPL) Class ActionContact Levi & Korsinsky - Newsfile
Shareholders of Replimune Group, Inc. Should Contact Levi & - GlobeNewswire
What earnings revisions data tells us about Replimune Group Inc.Weekly Profit Report & Community Trade Idea Sharing - Newser
How institutional ownership impacts Replimune Group Inc. stockQuarterly Growth Report & Weekly Top Performers Watchlists - Newser
Replimune Group, Inc. (REPL) Investors: September 22, 2025 Filing Deadline in Securities Class ActionContact Kessler Topaz Meltzer & Check, LLP - FinancialContent
Replimune Group Inc.’s volatility index tracking explainedMarket Volume Report & High Win Rate Trade Tips - Newser
Class Action Filed Against Replimune Group, Inc. (REPL)September 22, 2025 Deadline to JoinContact Levi & Korsinsky - MarketScreener
Lost Money on Replimune Group, Inc. (REPL)? Contact Levi & Korsinsky to Join Class Action Before September 22, 2025 - ACCESS Newswire
Is Replimune Group Inc. a candidate for recovery playMarket Activity Summary & Expert Verified Stock Movement Alerts - Newser
How to interpret RSI for Replimune Group Inc. stockEarnings Miss & Breakout Confirmation Alerts - Newser
Replimune Group, Inc. Class Action: The Gross Law Firm - GlobeNewswire
Time to SueWallSt? Levi & Korsinsky Files Lawsuit Over Replimune Group, Inc. Stock Losses - Stockhouse
Class Action Alert: Levi & Korsinsky Reminds Replimune Group, Inc. (REPL) Investors of September 22, 2025 Deadline - ACCESS Newswire
Class Action Lawsuit Filed Against Replimune Group, Inc. (REPL)Recover LossesContact Levi & Korsinsky Before September 22, 2025 - ACCESS Newswire
Contact The Gross Law Firm by September 22, 2025 Deadline to Join Class Action Against Replimune Group, Inc.(REPL) - PR Newswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
How to recover losses in Replimune Group Inc. stockPortfolio Risk Report & Free Long-Term Investment Growth Plans - Newser
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Fraud Lawsuit with the Schall Law Firm - MarketScreener
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL - FinancialContent
Replimune Group, Inc. (REPL) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of September 22, 2025 Deadline - ACCESS Newswire
2025-08-17 | REPL SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Replimune Group, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! | NDAQ:REPL | Press Release - Stockhouse
Is Replimune Group Inc. trending in predictive chart models2025 AllTime Highs & Verified Chart Pattern Trade Signals - Newser
REPL Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against Replimune Group, Inc. (REPL)Contact Kessler Topaz Meltzer & Check, LLP - FinancialContent
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Replimune - GlobeNewswire
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Replimune Group, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – REPL - GlobeNewswire Inc.
Bragar Eagel & Squire, P.C. Reminds Investors of Class - GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming DeadlinesREPL - PR Newswire
ROSEN, THE FIRST FILING FIRM, Encourages Replimune Group, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by The FirmREPL - ACCESS Newswire
Lawsuit filed for Investors who lost money with shares of Replimune Group, Inc. (NASDAQ: REPL) - openPR.com
Shareholders of Replimune Group, Inc. (REPL): Protect Your Rights Before September 22, 2025Contact Levi & Korsinsky - ACCESS Newswire
Faruqi & Faruqi Reminds Replimune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 22, 2025REPL - MarketScreener
Class Action Announcement for Replimune Group, Inc. (REPL): Kessler Topaz Meltzer & Check, LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Replimune Group, Inc. - MarketScreener
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 22, 2025 in Replimune Group, Inc. LawsuitREPL - PR Newswire
Replimune Group Stock Soars 17.76% Amid FDA Rejection Lawsuit - AInvest
Momentum divergence signals in Replimune Group Inc. chart2025 Biggest Moves & Safe Swing Trade Setups - Newser
Replimune Group’s SWOT analysis: oncology biotech stock faces FDA hurdles - Investing.com
Replimune Group, Inc. shares rise 11.59% after-hours following securities class action lawsuits. - AInvest
REPL LAWSUIT ALERT: Levi & Korsinsky Notifies Replimune Group, Inc. Investors of a Class - Bluefield Daily Telegraph
Replimune Group Inc Stock (REPL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Replimune Group Inc Stock (REPL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Astley-Sparke Philip | Director |
May 20 '25 |
Sale |
8.06 |
32,279 |
260,169 |
1,405,071 |
| Xynos Konstantinos | Chief Medical Officer |
May 20 '25 |
Sale |
8.06 |
7,952 |
64,093 |
146,933 |
| Schwendenman Andrew | Chief Accounting Officer |
May 20 '25 |
Sale |
8.05 |
3,287 |
26,460 |
68,284 |
| Patel Sushil | Chief Executive Officer |
May 20 '25 |
Sale |
8.06 |
25,105 |
202,346 |
343,576 |
| Hill Emily Luisa | Chief Financial Officer |
May 20 '25 |
Sale |
8.05 |
2,535 |
20,407 |
143,522 |
| Sarchi Christopher | Chief Commercial Officer |
May 20 '25 |
Sale |
8.05 |
3,749 |
30,179 |
128,296 |
| Patel Sushil | Chief Executive Officer |
Dec 16 '24 |
Sale |
12.42 |
10,000 |
124,200 |
202,014 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):